An Investigator-initiated, Open-Label Clinical Study of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Latest Information Update: 02 Dec 2025
At a glance
- Drugs CircFAM53B mRNA vaccine (Primary) ; Toripalimab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 02 Dec 2025 New trial record